Streptococcus pneumoniae is a primary cause of illness and death among children younger than 5 years in China. The heptavalent pneumococcal conjugate vaccine (PCV7) was t'/> Impact of the Pneumococcal Heptavalent Conjugated Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Children 2-5-Year-Old in Beijing, China
首页> 外文期刊>World Journal of Vaccines >Impact of the Pneumococcal Heptavalent Conjugated Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Children 2-5-Year-Old in Beijing, China
【24h】

Impact of the Pneumococcal Heptavalent Conjugated Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Children 2-5-Year-Old in Beijing, China

机译:肺炎球菌七价结合疫苗对北京2-5岁儿童鼻咽链球菌携带和抗菌药敏性的影响

获取原文
       

摘要

style="text-align:justify;"> Streptococcus pneumoniae is a primary cause of illness and death among children younger than 5 years in China. The heptavalent pneumococcal conjugate vaccine (PCV7) was the only conjugated vaccine (PCV) available in China from 2008 to 2013. This randomized, controlled, open-label study conducted at 46 Beijing clinics involved 3281 healthy 2-5-year-old Chinese children, randomized 1:1 to receive one dose of the S. pneumoniae heptavalent conjugated vaccine (PCV7) (n = 1643) or Haemophilus influenzae type b conjugate vaccine (Hib) (n = 1638). The main objective of this study was to investigate the impact of PCV7 against that of Hib vaccination in the nasopharyngeal S. pneumoniae colonization in healthy Chinese children. Nasopharyngeal (NP) samples for culture, serotyping and antimicrobial susceptibility testing were collected before vaccination and at Day 60 and 180 post-vaccination. A total 3281 children were enrolled in the study. Demographic characteristics were similar among both study groups: 1641 children received PCV7. Before immunization, S. pneumoniae was isolated in 338 and 360 children in the PCV7 (144 PCV7 isolates) and Hib groups (145 PCV7 isolates), respectively. At Day 180, PCV7 vaccination was more effective than Hib vaccination in reduction NP carriage (20.2% [P = 0.052]) and new acquisition (19.0% [P = 0.066]). When reductions in NP carriage and new acquisition of PCV7 VT plus 6A was analyzed, reduction in the PCV7 vaccinated group achieved statistical significance (P = 0.034 and P = 0.042 versus Hib, respectively). NP carriage of NVT increased in both groups (P = 0.305 between study groups at Day 180). PCV7 decreased NP carriage of non-susceptible VT to amoxicillin (P = 0.000), ceftriaxone (P = 0.047) and MDR (P = 0.024) versus Hib. PCV7 vaccination in Chinese children 2 to 5 years of age was more effective than vaccination with Hib in the reduction of S. pneumoniae nasopharyngeal carriage, new acquisition and non-susceptible isolates.
机译:style =“ text-align:justify;”> 肺炎链球菌是中国5岁以下儿童患病和死亡的主要原因。七价肺炎球菌结合疫苗(PCV7)是2008年至2013年间中国唯一可用的结合疫苗(PCV)。这项在北京46家诊所进行的随机对照开放标签研究涉及3281名2-5岁的中国健康儿童,按照1:1的比例随机分配,以接受一剂 S。肺炎七价结合疫苗(PCV7)(n = 1643)或流感嗜血杆菌b型结合疫苗(Hib)(n = 1638)。这项研究的主要目的是调查PCV7对鼻咽 S中Hib疫苗的影响。中国健康儿童的肺炎菌定植。在接种疫苗之前以及接种后第60天和180天收集用于培养,血清分型和抗菌药敏性测试的鼻咽(NP)样品。该研究总共招募了3281名儿童。两个研究组的人口统计学特征相似:1641名儿童接受了PCV7。免疫前, S。分别在PCV7(144个PCV7分离株)和Hib组(145个PCV7分离株)的338名和360名儿童中分离出肺炎。在第180天,在减少NP携带(20.2%[ P = 0.052])和新获得疫苗(19.0%[ P = 0.066])方面,PCV7疫苗的免疫接种比Hib疫苗更有效。 )。当分析NP携带减少和PCV7 VT加6A的新获得量时,接种PCV7的组减少达到统计学显着性(相对于Hib, P = 0.034和 P = 0.042,分别)。两组中NVT的NP携带量均增加(第180天研究组之间的 P = 0.305)。 PCV7降低了非敏感性VT对阿莫西林( P = 0.000),头孢曲松钠( P = 0.047)和MDR( P = 0.024)的NP转运)与Hib。在2至5岁的中国儿童中,PCV7疫苗接种比Hib疫苗接种更有效地减少了 S。肺炎鼻咽携带,新获得的和非敏感分离株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号